Merus

Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapies, called Multiclonics®. Multiclonics® are manufactured using industry-standard processes and have been observed to share several characteristics with conventional human monoclonal antibodies, such as long half-life and low immunogenicity, in preclinical and clinical studies.